Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ontology of Medically Related Social Entities Resource Report Resource Website |
Ontology of Medically Related Social Entities (RRID:SCR_003439) | OMRSE | data or information resource, ontology, controlled vocabulary | An ontology covering the domain of social entities that are related to health care, such as demographic information (social entities for recording gender (but not sex) and marital status, for example) and the roles of various individuals and organizations (patient, hospital, etc.) | owl, medicine, health care, demographic |
is listed by: BioPortal is listed by: OBO is listed by: Google Code is related to: Information Artifact Ontology |
Free, Available for download, Freely available | nlx_157534 | http://purl.bioontology.org/ontology/OMRSE http://purl.obolibrary.org/obo/omrse.owl |
SCR_003439 | 2026-02-14 02:00:49 | 0 | |||||||
|
Innovative Medicines Initiative Resource Report Resource Website 100+ mentions |
Innovative Medicines Initiative (RRID:SCR_003754) | IMI | organization | Initiative to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by initiating and managing consortia composed of the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. IMI is a public-private partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), with a timeframe separated into two phases (2008-2013, 2014-2024) that are each defined by unique research agendas. The first phase (2008 2013) had four pillars that defined the focus of its research agenda: * Predicting safety: evaluating the safety of a compound during the pre-clinical phase of the development process and the later phases in clinical development. * Predicting efficacy: improving the ability to predict how a drug will interact in humans and how it may produce a change in function. * Knowledge management: utilization of information and data for predicting safety and efficacy. * Education and training: closing existing training gaps in the drug development process. Some of the consortia managed under IMI focused on specific health issues while others focused on broader challenges in drug development. Additionally, IMI launched a number of education and training projects during its first phases. The goal of the second phase (IMI2, 2014-2024) is to develop next generation vaccines and drugs. The focus is on delivering the right prevention and treatment for the right patient at the right time. There is a strong focus on the development of new medicines with an emphasis on tools and methods that accelerate patient access to new medicines. IMI2's agenda can be defined by four axes of research: * target validation and biomarker research (efficacy and safety) * adoption of innovative clinical trial paradigms * innovative medicines * patient-tailored adherence programs As part of its distinct goals, IMI2 aims to deliver: * 30% better success rate in clinical trials of priority medicines identified by the WHO; clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in five years; * new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer's disease. | drug development, drug, tool development, biomarker, data sharing, target validation, safety, efficacy, clinical trial, medicine, adherence program, vaccine, consortium, diagnostic marker, oncology, drug discovery |
is listed by: Consortia-pedia is related to: AddNeuroMed is related to: European Federation of Pharmaceutical Industries and Associations has parent organization: European Union has parent organization: European Federation of Pharmaceutical Industries and Associations is parent organization of: AddNeuroMed |
European Union FP7 ; Horizon 2020 ; EFPIA ; Other life science industries or organizations |
Wikidata: Q1664196, nlx_157984, grid.454814.8, ISNI: 0000 0004 0577 0821 | https://ror.org/019af4n30 | SCR_003754 | 2026-02-14 02:00:52 | 275 | |||||||
|
Global Health Innovative Technology Fund Resource Report Resource Website 10+ mentions |
Global Health Innovative Technology Fund (RRID:SCR_003753) | GHIT Fund, GHIT | institution | A consortium that focuses their efforts on discovering and developing new pharmaceutical drugs, vaccines (both preventive and therapeutic) and diagnostics against the infectious diseases that are prevalent in developing countries. The initial targets are those disorders designated by WHO as neglected tropical diseases prevalent in developing nations. The consortium aims to facilitate international partnerships that enable Japanese technology, innovations, and insights to play a more direct role in improving global health. Another goal of GHIT is to develop a new drug-discovery screening platform to assist the screening of compound libraries housed within Japanese companies and academic institutions. The vision is to have Japanese research organizations donate compounds, with the Fund reimbursing screening costs and leveraging screening programs of existing product-development partners. | global health, health, drug development, biomarker, consortium, drug, vaccine, diagnostics, healthcare, developing country, disease | is listed by: Consortia-pedia | Government of Japan ; Bill and Melinda Gates Foundation ; Pharmaceutical industry |
grid.475132.6, nlx_157983 | https://ror.org/02yfqyv95 | SCR_003753 | 2026-02-14 02:00:35 | 16 | |||||||
|
Medical Dictionary for Regulatory Activities Resource Report Resource Website 1+ mentions |
Medical Dictionary for Regulatory Activities (RRID:SCR_003751) | MEDDRA | data or information resource, ontology, controlled vocabulary | Ontology of Medical Dictionary for Regulatory Activities Terminology (MedDRA) | umls | is listed by: BioPortal | nlx_157471 | SCR_003751 | 2026-02-14 02:00:30 | 2 | |||||||||
|
Coca-Cola Company Resource Report Resource Website 1+ mentions |
Coca-Cola Company (RRID:SCR_003749) | Coca-Cola, KO | commercial organization | An American multinational beverage corporation and manufacturer, retailer and marketer of nonalcoholic beverage concentrates and syrups, which is headquartered in Atlanta, Georgia. (Wikipedia) It is the world's largest beverage company, refreshing consumers with more than 500 sparkling and still brands. | beverage | Crossref funder ID: 100004367, ISNI: 0000 0004 0504 2170, grid.451378.c, Wikidata: Q3295867, nlx_158091 | https://ror.org/00yc8qw13 | SCR_003749 | KO, The Coca-Cola Company, Coca-Cola | 2026-02-14 02:00:35 | 2 | ||||||||
|
Seven Hills Bioreagents Resource Report Resource Website 1+ mentions |
Seven Hills Bioreagents (RRID:SCR_003748) | commercial organization | An Antibody supplier | nlx_152458 | SCR_003748 | 2026-02-14 02:00:51 | 3 | ||||||||||||
|
RevMan Resource Report Resource Website 10000+ mentions |
RevMan (RRID:SCR_003581) | RevMan | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 5, 2023.A software package that does meta-analysis and provides results in tabular format and graphically., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. |
is listed by: OMICtools is listed by: SoftCite |
THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_00244 | SCR_003581 | Review Manager | 2026-02-14 02:00:29 | 12961 | ||||||||
|
Torrey Pines Biolabs Resource Report Resource Website 100+ mentions |
Torrey Pines Biolabs (RRID:SCR_003580) | commercial organization | An Antibody supplier | nlx_152481 | SCR_003580 | Torrey Pines Biolabs Inc., Torrey Pines Biolabs Inc | 2026-02-14 02:00:52 | 376 | |||||||||||
|
Charles Stark Draper Laboratory Resource Report Resource Website 1+ mentions |
Charles Stark Draper Laboratory (RRID:SCR_003736) | Draper | nonprofit organization | A not-for-profit research and development laboratory focused on the design, development, and deployment of advanced technological solutions for the nation's most challenging and important problems in security, space exploration, healthcare, and energy. Their expertise includes the areas of guidance, navigation, and control systems; fault-tolerant computing; advanced algorithms and software solutions; modeling and simulation; and MEMS and multichip module technology. With a strong commitment to delivering working solutions to their sponsors, they apply their expertise to a variety of domains, including autonomous air, land, sea, and space systems; information integration; distributed sensors and networks; precision-guided munitions; and biomedical engineering; chemical/biological defense; and energy system modeling and management. When appropriate for the needs of their sponsors, they will work with commercial partners to transition their technology to commercial production. | engineering, technology, research, defense, space, biomedical, energy, service |
is related to: Massachusetts Institute of Technology; Massachusetts; USA; is parent organization of: Center for Integration of Medicine and Innovative Technology |
Acknowledgement required, Non-commercial | grid.417533.7, Crossref funder ID: 100006353, nlx_157942, ISNI: 0000 0004 0634 6125, Wikidata: Q2876029 | https://ror.org/04378d909 | SCR_003736 | Draper Laboratory, The Charles Stark Draper Laboratory Inc | 2026-02-14 02:00:52 | 1 | ||||||
|
PyroBayes Resource Report Resource Website 1+ mentions |
PyroBayes (RRID:SCR_003757) | PyroBayes | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 6, 2023. A base caller for pyrosequences from the 454 Life Sciences sequencing machines. | is listed by: OMICtools | PMID:18193056 | THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_01155 | SCR_003757 | 2026-02-14 02:00:35 | 3 | ||||||||
|
Oxford Nanopore Technologies Resource Report Resource Website 100+ mentions |
Oxford Nanopore Technologies (RRID:SCR_003756) | Oxford Nanopore | commercial organization | Commercial organization developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The instruments GridION and MinION are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security / defence. | nanopore technology, dna, rna, protein, small molecule, molecule, analysis, nanopore, nanopore sensing |
is related to: READNA is related to: Pychopper |
nlx_158233 | SCR_003756 | Oxford Nanopore Technologies Ltd | 2026-02-14 02:00:51 | 399 | ||||||||
|
PSTC Nephrotoxicity Biomarkers Resource Report Resource Website |
PSTC Nephrotoxicity Biomarkers (RRID:SCR_003709) | PSTC Nephrotoxicity Biomarkers | data or information resource, narrative resource, standard specification | Urinary kidney biomarkers (KIM-1, albumin, total protein, 2-microglobulin, cystatin C, clusterin and trefoil factor-3) that are considered acceptable biomarkers for the detection of acute drug-induced nephrotoxicity in rats and can be included along with traditional clinical chemistry markers and histopathology in toxicology studies. These biomarkers may be used voluntarily as additional evidence of nephrotoxicity in nonclinical safety assessment studies to complement the standard data (BUN and sCr). In ROC analyses, some of these biomarkers showed better sensitivity and specificity than BUN and sCr relative to histopathological alterations considered to be the gold standard when tested with a limited number of nephrotoxicant and control compounds. | biomarker, drug development, drug, urinary, urinary biomarker, gold standard, kim-1, albumin, total protein, beta2-microglobulin, cystatin c, clusterin, trefoil factor-3, kidney, nonclinical |
is recommended by: U.S. Food and Drug Administration has parent organization: Drug Development Tools Qualification Programs has parent organization: Predictive Safety Testing Consortium |
Nephrotoxicity, Drug-induced nephrotoxicity | Public | nlx_157890 | SCR_003709 | Predictive Safety and Testing Consortium Drug-induced Nephrotoxicity Biomarkers, PSTC NWG Drug-induced Nephrotoxicity Biomarkers | 2026-02-14 02:00:35 | 0 | ||||||
|
Brandeis University; Massachusetts; USA Resource Report Resource Website |
Brandeis University; Massachusetts; USA (RRID:SCR_003669) | university | Private research university located in the Boston suburb of Waltham, Massachusetts. Founded in 1948 as a non-sectarian, coeducational institution sponsored by the Jewish community, Brandeis was established on the site of the former Middlesex University. |
is parent organization of: Paper Rejection Repository is parent organization of: Enhancer Trap Line Browser is parent organization of: Brandeis University Neuroscience Undergraduate Program is parent organization of: Brandeis University Neuroscience Graduate Program is parent organization of: Research Network in Early Experience and Brain Development is parent organization of: Neurofitter is parent organization of: Brandeis University Light Microscopy Core Facility is parent organization of: Brandeis University Louise Mashal Gabbay Cellular Visualization Center Electron Microscopy Core Facility |
nlx_50198, Wikidata:Q49119, ISNI:0000 0004 1936 9473, grid.253264.4, Crossref funder ID:100007864 | https://ror.org/05abbep66 | SCR_003669 | 2026-02-14 02:00:50 | 0 | ||||||||||
|
eBioscience Resource Report Resource Website 50+ mentions |
eBioscience (RRID:SCR_003660) | commercial organization | An Antibody supplier | nlx_152349 | SCR_003660 | 2026-02-14 02:00:52 | 70 | ||||||||||||
|
Signalway Resource Report Resource Website 10+ mentions |
Signalway (RRID:SCR_003659) | SAB | commercial organization | An Antibody supplier | nlx_152462 | SCR_003659 | Signalway Antibody Co. Ltd | 2026-02-14 02:00:35 | 11 | ||||||||||
|
Experimental Factor Ontology Resource Report Resource Website 10+ mentions |
Experimental Factor Ontology (RRID:SCR_003574) | EFO | data or information resource, ontology, controlled vocabulary | An application focused ontology modelling the experimental factors in ArrayExpress and Gene Expression Atlas. It has been developed to increase the richness of the annotations that are currently made in the ArrayExpress repository, to promote consistent annotation, to facilitate automatic annotation and to integrate external data. The ontology describes cross-product classes from reference ontologies in area such as disease, cell line, cell type and anatomy. The methodology employed in the development of EFO involves construction of mappings to multiple existing domain specific ontologies, such as the Disease Ontology and Cell Type Ontology. This is achieved using a combination of automated and manual curation steps and the use of a phonetic matching algorithm. The ontology is evaluated with use cases from the ArrayExpress repository and ArrayExpress Atlas. You may also browse the EFO in the NCBO Bioportal. Term submissions are welcome. | gene expression, owl, experimental factor, disease, cell line, cell type, anatomy, gold standard |
is listed by: BioPortal is related to: ArrayExpress is related to: ArrayExpress is related to: Gene Expression Atlas has parent organization: European Bioinformatics Institute |
European Molecular Biology Laboratory ; European Union FELICS contract 021902; European Union EMERALD LSHG-CT-2006-037686; European Union Gen2Phen contract 200754 |
PMID:20200009 | The community can contribute to this resource | nlx_11363 | SCR_003574 | 2026-02-14 02:00:29 | 16 | ||||||
|
RAREMETAL Resource Report Resource Website 10+ mentions |
RAREMETAL (RRID:SCR_003573) | RAREMETAL | software resource | A software program that facilitates the meta-analysis of rare variants from genotype arrays or sequencing. | bio.tools |
is listed by: OMICtools is listed by: bio.tools is listed by: Debian has parent organization: University of Michigan; Ann Arbor; USA |
PMID:24894501 | biotools:raremetal, OMICS_00243 | https://bio.tools/raremetal | SCR_003573 | 2026-02-14 02:00:52 | 22 | |||||||
|
Adverse Event Reporting Ontology Resource Report Resource Website 1+ mentions |
Adverse Event Reporting Ontology (RRID:SCR_003571) | AERO | data or information resource, ontology, controlled vocabulary | An ontology aimed at supporting clinicians at the time of data entry, increasing quality and accuracy of reported adverse events. | owl, rdf, aero, bfo, ogms, iao, adverse event, clinician, health |
is listed by: BioPortal is listed by: OBO is listed by: Google Code is related to: Information Artifact Ontology |
New BSD License (code), Creative Commons Attribution License (content) | nlx_11209 | http://bioportal.bioontology.org/ontologies/1580 http://www.obofoundry.org/cgi-bin/detail.cgi?id=AERO http://purl.obolibrary.org/obo/aero.owl http://purl.obolibrary.org/obo/aero |
SCR_003571 | 2026-02-14 02:00:50 | 1 | |||||||
|
Corpus Callosum Thickness Profile Analysis Pipeline Resource Report Resource Website |
Corpus Callosum Thickness Profile Analysis Pipeline (RRID:SCR_003575) | ccsegthickness | software resource | An end-to-end pipeline for corpus callosum processing that provides automated midsagittal alignment, CC segmentation with a quality control tool, and thickness profile generation. Groupwise analysis is facilitated by permutation testing with FWER and FDR multiple comparison correction. Results display is facilitated by a display script that shows p-values on a 3D pipe representation of a CC. This pipeline is implemented in MATLAB and requires the Image Processing Toolbox. There are plans to implement it completely in Python. | linux, matlab, mr, nifti-1, posix/unix-like, corpus callosum | is listed by: NeuroImaging Tools and Resources Collaboratory (NITRC) | PMID:24968872 | GNU General Public License | nlx_157716 | SCR_003575 | 2026-02-14 02:00:50 | 0 | |||||||
|
Medical Diagnostic Categories - Diagnosis Related Groups Resource Report Resource Website |
Medical Diagnostic Categories - Diagnosis Related Groups (RRID:SCR_003725) | MDCDRG | data or information resource, ontology, controlled vocabulary | Ontology of Medical Diagnostic Categories-Diagnosis Related Groups | owl | is listed by: BioPortal | nlx_157470 | SCR_003725 | 2026-02-14 02:00:51 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
